BidaskClub lowered shares of Bruker (NASDAQ:BRKR) from a buy rating to a hold rating in a report issued on Tuesday, December 18th.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Bruker from a hold rating to a strong-buy rating and set a $38.00 price target for the company in a research note on Monday, November 12th. Morgan Stanley downgraded Bruker from an equal weight rating to an underweight rating and boosted their price target for the company from $31.00 to $32.00 in a research note on Thursday, September 20th. ValuEngine downgraded Bruker from a buy rating to a hold rating in a research note on Friday, September 21st. Finally, UBS Group began coverage on Bruker in a research note on Tuesday, October 9th. They set a sell rating and a $30.00 price objective for the company. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Bruker currently has an average rating of Hold and a consensus target price of $35.57.
NASDAQ:BRKR traded up $0.70 during trading hours on Tuesday, hitting $33.37. The company had a trading volume of 549,600 shares, compared to its average volume of 838,137. Bruker has a 52 week low of $26.10 and a 52 week high of $36.38. The stock has a market cap of $5.06 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 1.79 and a beta of 1.35. The company has a quick ratio of 1.32, a current ratio of 2.24 and a debt-to-equity ratio of 0.27.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.07. Bruker had a net margin of 5.24% and a return on equity of 27.46%. The firm had revenue of $466.60 million for the quarter, compared to analysts’ expectations of $451.88 million. During the same quarter in the previous year, the business posted $0.29 EPS. The company’s quarterly revenue was up 7.1% on a year-over-year basis. On average, analysts expect that Bruker will post 1.4 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 21st. Stockholders of record on Monday, December 3rd were issued a dividend of $0.04 per share. The ex-dividend date of this dividend was Friday, November 30th. This represents a $0.16 annualized dividend and a dividend yield of 0.48%. Bruker’s dividend payout ratio (DPR) is 13.22%.
Several institutional investors and hedge funds have recently modified their holdings of BRKR. SG Americas Securities LLC purchased a new stake in Bruker during the 2nd quarter valued at $101,000. Sun Life Financial INC purchased a new stake in Bruker during the 2nd quarter valued at $163,000. Crossmark Global Holdings Inc. purchased a new stake in Bruker in the third quarter worth $205,000. Private Advisor Group LLC purchased a new stake in Bruker in the third quarter worth $210,000. Finally, GAM Holding AG purchased a new stake in Bruker in the third quarter worth $211,000. 64.85% of the stock is currently owned by institutional investors and hedge funds.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Recommended Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.